Xyntha
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Xyntha (Pfizer) is a B-domain deleted recombinant factor VIII (rfVIII) product, approved in the US and EU for the prevention and treatment of bleeding episodes in patients with hemophilia A. Xyntha is produced through a similar manufacturing process as its predecessor, ReFacto (rfVIII). However, the process has been modified to allow for the elimination of animal- and human-derived proteins, producing a purer recombinant factor product. Wyeth submitted a Biologics License Application for Xyntha in 2007 based on these manufacturing modifications, which was approved in 2008. Xyntha is marketed as ReFacto AF in Europe.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Xyntha : Hemophilia
LIST OF FIGURES8 Figure 33: Eloctate for hemophilia – SWOT analysis
9 Figure 34: Datamonitor Healthcare’s drug assessment summary of Eloctate for hemophilia
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xyntha for hemophilia
12 Figure 4: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES5 Table 1: Xyntha drug profile
7 Table 2: Xyntha pivotal trial data in hemophilia
13 Table 3: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Idelvion 
Sign up to the